| A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis SJ Kim, DH Yoon, A Jaccard, WJ Chng, ST Lim, H Hong, Y Park, ... The lancet oncology 17 (3), 389-400, 2016 | 357 | 2016 |
| EGFR mutation and brain metastasis in pulmonary adenocarcinomas DY Shin, CH Kim, S Park, HJ Baek, SH Yang Journal of Thoracic Oncology 9 (2), 195-199, 2014 | 316 | 2014 |
| The incidence, risk factors and prognostic implications of venous thromboembolism in patients with gastric cancer KW Lee, SM Bang, S Kim, HJ Lee, DY Shin, Y Koh, YG Lee, Y Cha, ... Journal of Thrombosis and Haemostasis 8 (3), 540-547, 2010 | 108 | 2010 |
| Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving … BB Park, WS Kim, C Suh, DY Shin, JA Kim, HG Kim, WS Lee Annals of hematology 94, 1845-1851, 2015 | 60 | 2015 |
| Clinical dissection of multicentric Castleman disease D Shin, YK Jeon, Y Hong, TM Kim, S Lee, D Kim, I Kim, S Yoon, DS Heo, ... Leukemia & Lymphoma 52 (8), 1517-1522, 2011 | 52 | 2011 |
| A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas SJ Kim, DY Shin, JS Kim, DH Yoon, WS Lee, H Lee, YR Do, HJ Kang, ... Annals of oncology 27 (4), 712-718, 2016 | 49 | 2016 |
| Phase II study of dovitinib in patients with castration-resistant prostate cancer (KCSG-GU11-05) YJ Choi, HS Kim, SH Park, BS Kim, KH Kim, HJ Lee, HS Song, DY Shin, ... Cancer research and treatment: official journal of Korean Cancer Association …, 2018 | 40 | 2018 |
| Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008) DH Yoon, SJ Kim, SH Jeong, DY Shin, SH Bae, J Hong, SK Park, ... Oncotarget 7 (51), 85584, 2016 | 39 | 2016 |
| Magnetic resonance imaging pattern of bone marrow involvement as a new predictive parameter of disease progression in newly diagnosed patients with multiple myeloma eligible … MK Song, JS Chung, JJ Lee, CK Min, JS Ahn, SM Lee, DY Shin, SH Bae, ... British journal of haematology 165 (6), 777-785, 2014 | 37 | 2014 |
| Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials KJ Suh, JY Lee, DY Shin, Y Koh, SM Bang, SS Yoon, S Park, I Kim, ... International Journal of Hematology 106, 229-239, 2017 | 35 | 2017 |
| Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma HJ Kang, SS Lee, BH Byun, KM Kim, I Lim, CW Choi, C Suh, WS Kim, ... Cancer chemotherapy and pharmacology 71, 945-953, 2013 | 35 | 2013 |
| Management of immune thrombocytopenia: Korean experts recommendation in 2017 JH Jang, JY Kim, YC Mun, SM Bang, YJ Lim, DY Shin, YB Choi, HY Yhim, ... Blood research 52 (4), 254-263, 2017 | 34 | 2017 |
| Depletion of nerve growth factor in chemotherapy-induced peripheral neuropathy associated with hematologic malignancies J Youk, YS Kim, JA Lim, DY Shin, Y Koh, ST Lee, I Kim PLoS One 12 (8), e0183491, 2017 | 33 | 2017 |
| Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma DY Shin, A Kim, HJ Kang, S Park, DW Kim, SS Lee Cancer Letters 364 (2), 89-97, 2015 | 32 | 2015 |
| RTK-RAS pathway mutation is enriched in myeloid sarcoma M Choi, YK Jeon, CH Sun, HS Yun, J Hong, DY Shin, I Kim, SS Yoon, ... Blood cancer journal 8 (5), 43, 2018 | 29 | 2018 |
| Noncanonical immune response to the inhibition of DNA methylation by Staufen1 via stabilization of endogenous retrovirus RNAs Y Ku, JH Park, R Cho, Y Lee, HM Park, MA Kim, K Hur, SY Byun, J Liu, ... Proceedings of the National Academy of Sciences 118 (13), e2016289118, 2021 | 28 | 2021 |
| Decreased vitamin C uptake mediated by SLC2A3 promotes leukaemia progression and impedes TET2 restoration J Liu, J Hong, H Han, J Park, D Kim, H Park, M Ko, Y Koh, DY Shin, ... British Journal of Cancer 122 (10), 1445-1452, 2020 | 28 | 2020 |
| Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma SJ Kim, DH Yoon, HJ Kang, JY Hong, HS Lee, SY Oh, HJ Shin, JH Kong, ... BMC cancer 19, 1-7, 2019 | 28 | 2019 |
| Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms J Hong, JH Lee, JM Byun, JY Lee, Y Koh, DY Shin, JO Lee, SM Hwang, ... Blood Advances 3 (22), 3700-3708, 2019 | 28 | 2019 |
| Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy H Park, J Youk, DY Shin, J Hong, I Kim, NJ Kim, JO Lee, SM Bang, ... BMC cancer 19, 1-9, 2019 | 27 | 2019 |
